What is already known on this topic

UK national prescribing data are usually available only at the practice level, and analysis of these data has shown a weak relation between antibiotic prescribing and drug resistance in infective organisms

Such analyses probably suffer from ecological bias, which arises when area level data obscure important associations between individual exposure and risk

What this study adds

At the practice level, there was no association between variation in antibiotic prescribing and resistance after adjustment for practice level factors such as fundholding status

Inclusion of individual prescribing data in a multilevel model revealed a highly significant association between exposure to trimethoprim or other antibiotics, particularly in the previous six months, and resistance to trimethoprim

These results show that recent antibiotic exposure increases the risk of colonisation or infection by drug resistant bacteria and show the added value of analysis of data about individual patient prescribing

quality, patient specific data is increasing in Britain and elsewhere,²¹ though the use of data may be restricted by legislation.²²

Conclusion

Our results support efforts to reduce unnecessary prescribing of antibiotics in the community.²³ Clear demonstration of the added value of individual data will be important in the debate about practical and reasonable methods for obtaining consent for record linkage research.^{24 25}

MEMO is a member of the MRC Health Services Research Collaboration.

Participants: See bmj.com

Funding: The study was funded by a grant from the Chief Scientist Office.

Competing interests: TMM serves on advisory boards for Pfizer, Pharmacia, and Novartis but none relating to the current topic. PGD serves on advisory boards about antibiotic prescribing and resistance for Aventis and Pharmacia.

Ethical approval: The study protocol was approved by Tayside Research Ethics Committee.

1 Standing Medical Advisory Committee Subcommittee on Antibiotic Resistance. *The path of least resistance*. London: Department of Health, 1998.

- 2 Pauker SG, Rothberg M. Commentary: resist jumping to conclusions. *BMJ* 1999;318:1616-7.
- 3 Magee JT, Pritchard EL, Fitzgerald KA, Dunstan FDJ, Howard AJ. Antibiotic prescribing and antibiotic resistance in community practice: retrospective study, 1996-8. *BMJ* 1999;319:1239-40.
- 4 Priest P, Yudkin P, McNulty C, Mant D. Antibacterial prescribing and antibacterial resistance in English general practice: cross sectional study. *BMJ* 2001;323:1037-41.
- 5 Powsner SM, Wyatt JC, Wright P. Opportunities for and challenges of computerisation. *Lancet* 1998;352:1617-22.
- 6 Rosdahl VK, Pedersen KB, eds. *The Copenhagen recommendations. Report from the invitational EU conference on the microbial threat*. Copenhagen, Denmark: Ministry of Health, Ministry of Food, Agriculture and Fisheries. 1998:1-52.
- 7 Evans JMM, McDevitt DG, MacDonald TM. The Tayside Medicines Monitoring Unit (MEMO): a record-linkage system for pharmacovigilance. *Pharmaceutical Medicine* 1995;9:177-84.
- 8 McLoone P. *Carstairs codes for Scottish postcode sectors from the 1991 census*. Glasgow: Public Health Research Unit, University of Glasgow, 1991.
- 9 Hillier SL, Magee JT, Howard AJ, Palmer SR. How strong is the evidence that antibiotic use is a risk factor for antibiotic-resistant, community-acquired urinary tract infection? *J Antimicrob Chemother* 2002;50:241-7.
- 10 Steinke DT, Seaton RA, Phillips G, MacDonald TM, Davey PG. Prior trimethoprim use and trimethoprim-resistant urinary tract infection: a nested case-control study with multivariate analysis for other risk factors. *J Antimicrob Chemother* 2001;47:781-7.
- 11 Harbarth S, Harris AD, Carmeli Y, Samore MH. Parallel analysis of individual and aggregated data on antibiotic exposure and resistance in gram-negative bacilli. *Clin Infect Dis* 2001;33:1462-8.
- 12 Hall AJ. Ecological studies and debate on rotavirus vaccine and intussusception. *Lancet* 2001;358:1197-8.
- 13 Bronzwaer SL, Cars O, Buchholz U, Molstad S, Goettsch W, Veldhuijzen IK, et al. A European study on the relationship between antimicrobial use and antimicrobial resistance. *Emerg Infect Dis* 2002;8:278-82.
- 14 Leibovici L, Berger R, Gruenewald T, Yahav J, Yehezkeili Y, Milo G, et al. Departmental consumption of antibiotic drugs and subsequent resistance: a quantitative link. *J Antimicrob Chemother* 2001;48:535-40.
- 15 Aarestrup FM. Characterization of glycopeptide-resistant enterococcus faecium (GRE) from broilers and pigs in Denmark: genetic evidence that persistence of GRE in pig herds is associated with coselection by resistance to macrolides. *J Clin Microbiol* 2000;38:2774-7.
- 16 Langlois BE, Cromwell GL, Stahly TS, Dawson KA, Hays VW. Antibiotic resistance of fecal coliforms after long-term withdrawal of therapeutic and subtherapeutic antibiotic use in a swine herd. *Appl Environ Microbiol* 1983;46:1433-4.
- 17 Chiew YF, Yeo SF, Hall LMC, Livermore DM. Can susceptibility to an antimicrobial be restored by halting its use? The case of streptomycin versus Enterobacteriaceae. *J Antimicrob Chemother* 1998;41:247-51.
- 18 Enne VI, Livermore DM, Stephens P, Hall LM. Persistence of sulphonamide resistance in *Escherichia coli* in the UK despite national prescribing restriction. *Lancet* 2001;357:1325-8.
- 19 Hartley CL, Richmond MH. Antibiotic resistance and survival of *E coli* in the alimentary tract. *BMJ* 1975;4:71-4.
- 20 Cohen PS, Laux DC. *E coli* colonization of the mammalian colon: understanding the process. *Recomb DNA Tech Bull* 1985;8:51-4.
- 21 Horsfield P. Trends in data recording by general practice teams: an analysis of data extracted from clinical computer systems by the PRIMIS project. *Inform Prim Care* 2002;10:227-34.
- 22 Al Shahi R, Warlow CP. Using patient identifiable data for observational research and audit. Overprotection could damage the public interest. *BMJ* 2000;321:1031-2.
- 23 Department of Health. *UK antimicrobial resistance strategy and action plan*. London: DoH, 2000.
- 24 Young AF, Dobson AJ, Byles JE. Health services research using linked records: who consents and what is the gain? *Aust N Z J Public Health* 2001;25:417-20.
- 25 Holman CD. The impracticable nature of consent for research use of linked administrative health records. *Aust N Z J Public Health* 2001;25:421-2.

(Accepted 12 March 2004)

Commentary: Legal issues of data anonymisation in research

Petra Wilson

European Health Management Association, Rue De La Science 4, 1000 Brussels, Belgium
Petra Wilson
associate director
petra.wilson@ehma.org

In this paper Donnan et al expertly demonstrate the value of anonymised individual data in medical research, showing that effects masked in aggregated data are clearly visible when individual data are used. However, the use of anonymised data raises interesting legal questions.

The MEMO researchers paid careful attention to protecting patient confidentiality for the 166 000 files

they used in the study, with the data being anonymised with purpose made software that was used by named staff whose employment contracts could be revoked in the event of breaches of patient confidentiality. Given the large amount of data involved, patients' individual consent could not be sought, but efforts were made to inform patients of the possible use of their medical data and their rights of privacy through the

publication of a patient information leaflet. One should not assume, however, that anonymising data for medical research is a clear and simple endeavour in which all one needs to do is follow this type of best practice.

The Data Protection Directive and the Data Protection Act

The protection of privacy of data is regulated in all member states of the European Union by national legislation drawn up in response to the Data Protection Directive (Directive 95/46/EC), which seeks to harmonise the rules of data protection throughout the Union (all current national data protection legislation can be found at http://europa.eu.int/comm/internal_market/privacy/index_en.htm).

The Directive provides that the use of anonymised data falls outside its remit: "the principles of protection shall not apply to data rendered anonymous in such a way that the data subject is no longer identifiable" (Recital 26). Thus, Donnan et al correctly state that the anonymised data in their study were not subject to the Data Protection Act 1998. This point was further clarified for England and Wales in a judgment of the Court of Appeal.¹

However, neither the directive nor national law explain how the process of anonymisation of nominative data is to occur. In the United Kingdom the Office of the Information Commissioner, the regulatory authority established under the Data Protection Act 1998, has issued a guidance note on the concept of "personal data," which states that, although anonymous data may fall outside the remit of English law, the act of anonymisation does not: "In anonymising personal data the data controller will be processing such data and, in respect of such processing, will still need to comply with the provisions of the Act."²

It seems then that a rather peculiar situation exists where, in order to anonymise data, one needs the consent of the data subjects.

In the case of medical research, two ways around this issue exist. Firstly, researchers may use (and anonymise) data without prior notification of the data subjects only if they can comply with the special provisions in the data protection legislation, which provide for sensitive data to be processed for the purposes of medical research only by a health professional or a person who owes a duty of confidentiality that is equivalent to that which would arise if that person were a health professional.³ Secondly, personal data may be used for research purposes without prior consent of the data subjects if a list of rigorous requirements are followed.⁴

Given the lack of clarity and the complexity of legally anonymising data, the time is ripe for regulators to address the role of anonymisation of data in medical research again. Anonymisation facilitates research and protects confidentiality, and every effort should be made to support its practice.

Recent research shows that most European citizens generally trust healthcare providers to treat their data with due respect for confidentiality: in a recent Eurobarometer survey 84% of EU

citizens reported that they trusted the medical profession in this way, although only 42% knew of the need to provide agreement for someone to use their personal information and their right to oppose some uses.⁵ Let us build on this trust by, on the one hand, providing good information on the use of data in medical research and, on the other, providing the proper legal framework for the use of anonymisation techniques as demonstrated by MEMO. Both at European and national level every effort should be made to make the best possible use of modern anonymisation technologies so that patients' privacy can be simply and effectively protected while vital medical research based on individual records continues.

Competing interests: None declared.

- 1 R v Department of Health, ex parte Source Informatics. [2000] 2 WLR 622.
- 2 *Data Protection Act 1998 legal guidance*. London: Office of the Information Commissioner, 2002.
- 3 *Data Protection Act 1998*. Sch. 3 para 8. London: Stationery Office, 1998.
- 4 *Data Protection Act 1998*. Section 33 (4). London: Stationery Office, 1998.
- 5 European Opinion Research Group. Special Eurobarometer 196: data protection. Available at http://europa.eu.int/comm/internal_market/privacy/lawreport_en.htm#actions (accessed 5 May 2004).

Corrections and clarifications

Lessons from developing nations on improving health care

We inadvertently omitted the acknowledgment in this Education and Debate article by Donald M Berwick (8 May, pp 1124-9). It should have read: "I thank Joe McCannon, Meera Kotagal, Frank Davidoff, Jane Roessner, and Val Weber for their help in preparing this manuscript. The paper is based on a plenary address delivered at the 3rd Asia Pacific Forum on Quality Improvement in Health Care, cosponsored by the Institute for Healthcare Improvement and the BMJ Publishing Group, in Auckland, New Zealand, 5 September 2003."

No mean feat

In this profile of Pramod Karan Sethi (who invented two prostheses, known as the Jaipur foot and the Jaipur limb (a below-the-knee prosthesis)) by Dinesh Singhal and Samiran Nundy, several inaccuracies may have misled readers (3 April, pp 789). It is the limb (not the foot, as we stated) that is tailor made (and takes 45 minutes to an hour to fit); the foot is taken from available stock. The costs for the foot and the limb are higher than stated—currently 250 rupees (£3; \$5.50; €4.70) and 1500 rupees respectively. The workshop that Dr Sethi helped to set up was in Phnom Penh, Cambodia (not in Vietnam, as we stated), although he did train technicians from Vietnam.

Minerva

Minerva wishes to correct her description of the Miners and General Workers Compensation Recovery Unit as a government scheme (31 January, p 296). The organisation is in fact an independent commercial venture and as such should not have been endorsed by the *BMJ*.